Agenda for October 2026 Gastrointestinal Advisory Committee meeting
Information on what the Gastrointestinal Advisory Committee will be considering at its upcoming meeting in October 2026.
Vedolizumab Subcutaneous (Branded as ENTYVIO) for Ulcerative colitis and Crohn’s Disease
The Committee will discuss vedolizumab as a subcutaneous injection option for people living with ulcerative colitis or Crohn’s disease, to maintain disease control after initial intravenous treatment.
This is an extract. The publication continues at the source.
Read the original at the source: https://www.pharmac.govt.nz/news-and-resources/news/agenda-for-october-2026-gastrointestinal-advisory-committee-meeting
Officially imported this from Pharmac’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Pharmac — imported from official source
- Official source
- https://www.pharmac.govt.nz/news-and-resources/news/rss RSS
- Imported
- October 03, 2026 20:43
- Versions
- 1 recorded
- Identity
https://www.pharmac.govt.nz/news-and-resources/news/agenda-for-october-2026-gastrointes...